Rare post marketing case reports of suicidality have emerged amongst people taking GLP1 receptor agonists for diabetes or obesity. What new data do we have on this, and where are global regulatory agencies at in their investigations?
Learn more: https://drsue.ca/2024/01/update-are-glp1-receptor-agonist-medications-for-weight-management-and-diabetes-associated-with-suicide-risk/
Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.
Rare post marketing case reports of suicidality have emerged amongst people taking GLP1 receptor agonists for diabetes or obesity. What new data do we have on this, and where are global regulatory agencies at in their investigations?
Learn more: https://drsue.ca/2024/01/update-are-glp1-receptor-agonist-medications-for-weight-management-and-diabetes-associated-with-suicide-risk/
Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.